Blood Test for Cardiac Protein Diagnoses Heart Attack
By LabMedica International staff writers Posted on 17 Nov 2011 |
A novel blood test for a cardiac biomarker has been used to determine whether a patient has had a heart attack.
The test measures a large protein known as cardiac myosin binding protein-C (cMyBP-C), which is released into the blood following a cardiac event.
Scientists at Loyola University Chicago (Maywood, IL, USA) quantified plasma levels of cMyBP-C by a sandwich enzyme-linked immunosorbent assay (ELISA) using capture monoclonal anti-cMyBP-C, E7 and a detection rabbit polyclonal antibody anti-cMyBP-CC0–C1. Plasma cardiac troponin (cTnI) levels were also measured by a commercial sandwich ELISA. To determine the sensitivity of the sandwich ELISA for cMyBP-C, the investigators defined the limit of detection values and quantification for lower and upper limits. The values of lower limit of quantification and upper limit of quantification were 0.02 ng/ml and 2,053 ng/ml, respectively.
Plasma samples were collected from 16 myocardial infarction) MI) patients and 11 normal healthy controls. Importantly, cMyBP-C and cTnI levels in the plasma samples of healthy controls were very low, 0.95 ± 0.34 ng/mL and 0.238 ± 0.07 ng/mL, respectively. Strikingly, the concentration of cMyBP-C in the plasma of MI patients was significantly increased to 227 ± 50 ng/mL, compared to controls and greater than plasma cTnI levels at 30 ± 9 ng/mL. The anti-cMyBP-C, E7 monoclonal antibody used in this study is a product Santa Cruz Biotechnology (Santa Cruz, CA, USA). The human cardiac troponin assay was produced by Calbiotech (San Diego, CA, USA).
Sakthivel Sadayappan, PhD, senior author of the study said, "This potentially could become the basis for a new test, used in conjunction with other blood tests, to help diagnose heart attacks. This is the beginning. A lot of additional studies will be necessary to establish cMyBP-C as a true biomarker for heart attacks." The authors concluded that future studies would determine the time course of release, peak concentrations, and half-life in the circulatory system. The study was available online since September 19, 2011, in the Journal of Molecular and Cellular Cardiology.
Related Links:
Loyola University Chicago
Santa Cruz Biotechnology
Calbiotech
The test measures a large protein known as cardiac myosin binding protein-C (cMyBP-C), which is released into the blood following a cardiac event.
Scientists at Loyola University Chicago (Maywood, IL, USA) quantified plasma levels of cMyBP-C by a sandwich enzyme-linked immunosorbent assay (ELISA) using capture monoclonal anti-cMyBP-C, E7 and a detection rabbit polyclonal antibody anti-cMyBP-CC0–C1. Plasma cardiac troponin (cTnI) levels were also measured by a commercial sandwich ELISA. To determine the sensitivity of the sandwich ELISA for cMyBP-C, the investigators defined the limit of detection values and quantification for lower and upper limits. The values of lower limit of quantification and upper limit of quantification were 0.02 ng/ml and 2,053 ng/ml, respectively.
Plasma samples were collected from 16 myocardial infarction) MI) patients and 11 normal healthy controls. Importantly, cMyBP-C and cTnI levels in the plasma samples of healthy controls were very low, 0.95 ± 0.34 ng/mL and 0.238 ± 0.07 ng/mL, respectively. Strikingly, the concentration of cMyBP-C in the plasma of MI patients was significantly increased to 227 ± 50 ng/mL, compared to controls and greater than plasma cTnI levels at 30 ± 9 ng/mL. The anti-cMyBP-C, E7 monoclonal antibody used in this study is a product Santa Cruz Biotechnology (Santa Cruz, CA, USA). The human cardiac troponin assay was produced by Calbiotech (San Diego, CA, USA).
Sakthivel Sadayappan, PhD, senior author of the study said, "This potentially could become the basis for a new test, used in conjunction with other blood tests, to help diagnose heart attacks. This is the beginning. A lot of additional studies will be necessary to establish cMyBP-C as a true biomarker for heart attacks." The authors concluded that future studies would determine the time course of release, peak concentrations, and half-life in the circulatory system. The study was available online since September 19, 2011, in the Journal of Molecular and Cellular Cardiology.
Related Links:
Loyola University Chicago
Santa Cruz Biotechnology
Calbiotech
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines